All Posts:clinical trials
-
Promising Phase III Melanoma Results Build on Research Conducted at Georgetown Lombardi
A promising new approach to preventing high-risk melanoma from recurring after surgery has yielded positive results in a large clinical trial, building on earlier research that included investigators and patients at Georgetown University’s Lombardi Comprehensive Cancer Center.
Category: Lombardi Stories
-
Preoperative Dual Immunotherapy Combination Shows Promising Activity in High-Risk Early-Stage HER2-Negative Breast Cancer
A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given prior to surgery for patients with high-risk, early-stage HER2-negative breast cancer, according to phase 2 clinical trial results from the ongoing I-SPY2 clinical trial platform.
Category: News Release
-
Clinical Study Deepens Understanding of Mesothelioma and Opens the Door to Potential Treatment Options
People with operable diffuse pleural mesothelioma may benefit from immunotherapy before and after surgery, based on results of a clinical trial exploring the sequence of treatment and the role of surgery for this difficult to treat cancer.
Category: News Release
-
ISPY2: A Unique, Flexible Breast Cancer Trial for Modern Times
The ISPY2 breast cancer clinical trial is a unique phase 2 study that offers a broad range of treatment options for patients with locally advanced breast cancer.
Category: Lombardi Stories
-
Experimental Therapy Shows Promise in Pancreatic Cancer Clinical Trial
Clinicians at Georgetown University’s Lombardi Comprehensive Cancer Center reported promising preliminary findings based on outcomes in the first six patients with metastatic pancreatic cancer enrolled in a phase 2 clinical trial of the experimental drug BXCL701 in combination with the immunotherapy drug pembrolizumab (Keytruda). Immunotherapy drugs alone have not shown to be responsive to pancreatic cancer.
Category: News Release
-
The Aspirin Conundrum: Navigating Negative Results, Age, Aging Dynamics and Equity
A new study examining the role of aspirin in breast cancer treatment reveals critical issues related to health equity and aging that have broad implications for cancer and other disease intervention trials, say researchers from Georgetown University’s Lombardi Comprehensive Cancer Center. They outline their concerns in an editorial accompanying the study’s findings published April 29 in the JAMA.
Category: News Release
-
Could a Georgetown Lab Finding Lead to New Treatment in Pancreatic Cancer?
For the first time, new research by Georgetown scientists shows potential to make immunotherapy effective in pancreatic cancer by combining it with a drug that makes cancer cells more responsive to immunotherapy. The research is now in a phase 2 clinical trial being tested in human patients.
Category: Lombardi Stories
-
Understanding Immunotherapy Resistance Leads to New Therapeutic Strategies — and Hope
Samir Khleif, MD, an immunologist and professor of oncology at Georgetown Lombardi, is working to understand why some cancers become resistant to immunotherapy, and how that resistance can be overcome.
Category: Lombardi Stories
-
Biology Behind New Drug Used to Treat Triple-Negative Breast Cancer Uncovered
How TTP488 (azeliragon), an experimental drug, impairs aggressive, triple-negative breast cancer from metastasizing has been uncovered at the cellular level, according to researchers at Georgetown University’s Lombardi Comprehensive Cancer Center.
Category: News Release
-
New Study Finds Personalized mRNA Vaccine Given with Immunotherapy Reduces Recurrence in High-Risk Melanoma Patients
A new study conducted by an international team of researchers, including clinical investigators at Georgetown University’s Lombardi Comprehensive Cancer Center, demonstrates that a personalized cancer mRNA vaccine combined with immunotherapy reduces recurrence and improves survival for people with advanced melanoma.
Category: Lombardi Stories